FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620282892> ?p ?o ?g. }

• W2620282892 endingPage "47860" @default.
• W2620282892 startingPage "47849" @default.
• W2620282892 abstract "// Bin Li 1 , Xunbo Jin 1 , Huilin Meng 1 , Bo Hu 1 , Tao Zhang 1 , Jiang Yu 1 , Shaoan Chen 1 , Xudong Guo 1 , Weiguo Wang 2 , Wei Jiang 3 and Jin Wang 4, 5 1 Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China 2 Department of Urology, Jining No.1 People’s Hospital, Jining 272011, Shandong, China 3 Department of Urology, Dongying People’s Hospital, Dongying 257091, Shandong, China 4 Department of Urology, Shandong Provincial Qianfoshan Hospital Affiliated to Shandong University, Jinan 250014, Shandong, China 5 School of Basic Medical Sciences, Shandong University, Jinan 250012, Shandong, China Correspondence to: Jin Wang, email: wjinsdu@163.com Keywords: prostate cancer, morin, paclitaxel-resistance, microRNA (miR)-155, GATA binding protein 3 (GATA3) Received: February 28, 2017     Accepted: April 21, 2017     Published: May 24, 2017 ABSTRACT Paclitaxel is a first-line microtubule-stabilizing drug in treating prostate cancer. However, most patients develop resistance and experience relapse. Morin (3,5,7,20,40-pentahydroxyflavone) is an anti-tumor flavonoid in a numerous types of cancer cells including breast, ovarian and lung cancers. We therefore researched the effects of morin as an adjuvant to paclitaxel in in treating DU145 and PC-3 cells in vitro and DU145 derived prostate cancers in nude mice models. The chemosensitivities of these cells to the treatments of morin and paclitaxel were tested through viability assays utilizing cell counting kit 8 (CCK-8) and apoptosis assays through flow cytometry analyses. MicroRNA (miRNA) microarray was employed to determine the changes in miRNA profile of morin treated DU145 cells. The results from microarrays were further certified by quantitative real-time reverse transcription-PCR (qRT-PCR). The underlying targets of miR-155 were verified using luciferase assays followed by Western blot assays. In the results, morin was capable of repressing the cell viabilities in the paclitaxel-treated cells. MiR-155might be an effective target that can be down-regulated in morin-treated cells. We also discovered that GATA binding protein 3 (GATA3) was directly repressed by miR-155, and the treatment of morin reversed the expression of GATA3. In conclusion, morin might be a potential adjuvant of paclitaxel in treating prostate cancer through regulating miR-155/GATA3 axis." @default.
• W2620282892 created "2017-06-05" @default.
• W2620282892 creator A5006913809 @default.
• W2620282892 creator A5013497114 @default.
• W2620282892 creator A5018244700 @default.
• W2620282892 creator A5030115905 @default.
• W2620282892 creator A5044434277 @default.
• W2620282892 creator A5054726963 @default.
• W2620282892 creator A5057435049 @default.
• W2620282892 creator A5058568961 @default.
• W2620282892 creator A5066401556 @default.
• W2620282892 creator A5083918639 @default.
• W2620282892 creator A5085956552 @default.
• W2620282892 date "2017-05-24" @default.
• W2620282892 modified "2023-10-03" @default.
• W2620282892 title "Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis" @default.
• W2620282892 cites W144423133 @default.
• W2620282892 cites W1505433891 @default.
• W2620282892 cites W1574141446 @default.
• W2620282892 cites W1576344981 @default.
• W2620282892 cites W1968038894 @default.
• W2620282892 cites W1974254202 @default.
• W2620282892 cites W1975410218 @default.
• W2620282892 cites W1980884243 @default.
• W2620282892 cites W1996787649 @default.
• W2620282892 cites W2003397087 @default.
• W2620282892 cites W2020522211 @default.
• W2620282892 cites W2023189987 @default.
• W2620282892 cites W2030495676 @default.
• W2620282892 cites W2032630075 @default.
• W2620282892 cites W2048178760 @default.
• W2620282892 cites W2048454522 @default.
• W2620282892 cites W2056760970 @default.
• W2620282892 cites W2080439368 @default.
• W2620282892 cites W2095058517 @default.
• W2620282892 cites W2112451226 @default.
• W2620282892 cites W2115466148 @default.
• W2620282892 cites W2116071996 @default.
• W2620282892 cites W2120292596 @default.
• W2620282892 cites W2123068764 @default.
• W2620282892 cites W2137881107 @default.
• W2620282892 cites W2139812008 @default.
• W2620282892 cites W2143626453 @default.
• W2620282892 cites W2154747925 @default.
• W2620282892 cites W2157175890 @default.
• W2620282892 cites W2158899005 @default.
• W2620282892 cites W2160098916 @default.
• W2620282892 cites W2160737079 @default.
• W2620282892 cites W2167057061 @default.
• W2620282892 cites W2167302066 @default.
• W2620282892 cites W2185193730 @default.
• W2620282892 cites W2230662962 @default.
• W2620282892 cites W2413623242 @default.
• W2620282892 cites W2527239283 @default.
• W2620282892 cites W2581141558 @default.
• W2620282892 doi "https://doi.org/10.18632/oncotarget.18133" @default.
• W2620282892 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5564610" @default.
• W2620282892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28599307" @default.
• W2620282892 hasPublicationYear "2017" @default.
• W2620282892 type Work @default.
• W2620282892 sameAs 2620282892 @default.
• W2620282892 citedByCount "51" @default.
• W2620282892 countsByYear W26202828922017 @default.
• W2620282892 countsByYear W26202828922018 @default.
• W2620282892 countsByYear W26202828922019 @default.
• W2620282892 countsByYear W26202828922020 @default.
• W2620282892 countsByYear W26202828922021 @default.
• W2620282892 countsByYear W26202828922022 @default.
• W2620282892 countsByYear W26202828922023 @default.
• W2620282892 crossrefType "journal-article" @default.
• W2620282892 hasAuthorship W2620282892A5006913809 @default.
• W2620282892 hasAuthorship W2620282892A5013497114 @default.
• W2620282892 hasAuthorship W2620282892A5018244700 @default.
• W2620282892 hasAuthorship W2620282892A5030115905 @default.
• W2620282892 hasAuthorship W2620282892A5044434277 @default.
• W2620282892 hasAuthorship W2620282892A5054726963 @default.
• W2620282892 hasAuthorship W2620282892A5057435049 @default.
• W2620282892 hasAuthorship W2620282892A5058568961 @default.
• W2620282892 hasAuthorship W2620282892A5066401556 @default.
• W2620282892 hasAuthorship W2620282892A5083918639 @default.
• W2620282892 hasAuthorship W2620282892A5085956552 @default.
• W2620282892 hasBestOaLocation W26202828921 @default.
• W2620282892 hasConcept C121608353 @default.
• W2620282892 hasConcept C126322002 @default.
• W2620282892 hasConcept C143998085 @default.
• W2620282892 hasConcept C2776438761 @default.
• W2620282892 hasConcept C2777292972 @default.
• W2620282892 hasConcept C2779723316 @default.
• W2620282892 hasConcept C2780192828 @default.
• W2620282892 hasConcept C502942594 @default.
• W2620282892 hasConcept C556039675 @default.
• W2620282892 hasConcept C71924100 @default.
• W2620282892 hasConceptScore W2620282892C121608353 @default.
• W2620282892 hasConceptScore W2620282892C126322002 @default.
• W2620282892 hasConceptScore W2620282892C143998085 @default.
• W2620282892 hasConceptScore W2620282892C2776438761 @default.
• W2620282892 hasConceptScore W2620282892C2777292972 @default.
• W2620282892 hasConceptScore W2620282892C2779723316 @default.

• next